BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Neurocrine Biosciences readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Neurocrine Biosciences's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06786624-810@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Osavampator: Phase 3 readout est. (NCT06786624)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: Stud
 y to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatm
 ent in Participants With Major Depressive Disorder (MDD)\nEstimated primar
 y completion: July 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/osavampator#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06786624
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911112-810@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Osavampator: Phase 3 readout est. (NCT06911112)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: NBI-
 1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as
  an Adjunctive Treatment in Participants With Major Depressive Disorder (M
 DD)\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/osavampator#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06911112
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963021-810@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Osavampator: Phase 3 readout est. (NCT06963021)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: NBI-
 1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as
  an Adjunctive Treatment in Participants With Major Depressive Disorder (M
 DD)\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/osavampator#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06963021
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288333-9469@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:NBI-1117570: Phase 2 readout est. (NCT07288333)
DESCRIPTION:NBI-1117570\, phase 2\, Schizophrenia.\nStudy: Evaluation of NB
 I-1117570 in Inpatient Adults With Schizophrenia\nEstimated primary comple
 tion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nb
 i-1117570#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07288333
URL:https://assetmemo.bio/drug/nbi-1117570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963034-9196@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Direclidine: Phase 3 readout est. (NCT06963034)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: NBI-1117568-SCZ3
 029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia\nEst
 imated primary completion: October 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/direclidine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06963034
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105098-9196@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Direclidine: Phase 3 readout est. (NCT07105098)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: NBI-1117568-SCZ3
 030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia\nEst
 imated primary completion: November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/direclidine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07105098
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07947368-10814@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Crinecerfont: Phase 3 readout est. (NCT07947368)
DESCRIPTION:Crinecerfont\, phase 3\, Congenital Adrenal Hyperplasia.\nStudy
 : Study to Evaluate the Effect of Crinecerfont on Androgen Reduction and R
 elated Outcomes in Adults With Classic Congenital Adrenal Hyperplasia (CAH
 )\nEstimated primary completion: January 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/crinecerfont#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07947368
URL:https://assetmemo.bio/drug/crinecerfont#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288320-9196@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Direclidine: Phase 2 readout est. (NCT07288320)
DESCRIPTION:Direclidine\, phase 2.\nStudy: An Assessment of Efficacy\, Safe
 ty\, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder
  With Current Mania\nEstimated primary completion: February 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/direclidine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07288320
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312189-9342@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ingrezza (Valbenazine): Phase 3 readout est. (NCT06312189)
DESCRIPTION:Ingrezza (Valbenazine)\, phase 3\, Huntington's Disease.\nStudy
 : Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Pa
 rticipants With Chorea Associated With Huntington Disease in Canada\nEstim
 ated primary completion: April 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/valbenazine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06312189
URL:https://assetmemo.bio/drug/valbenazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196501-810@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Osavampator: Phase 3 readout est. (NCT07196501)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Tre
 atment in Participants With Major Depressive Disorder (MDD)\nEstimated pri
 mary completion: July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/osavampator#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07196501
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966401-810@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Osavampator: Phase 3 readout est. (NCT06966401)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: Long
 -Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adj
 unctive Treatment in Participants With Major Depressive Disorder (MDD)\nEs
 timated primary completion: May 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/osavampator#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06966401
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227818-9196@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Direclidine: Phase 3 readout est. (NCT07227818)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: Efficacy of NBI-
 1117568 in Preventing Relapse in Adults With Schizophrenia\nEstimated prim
 ary completion: July 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/direclidine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07227818
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07114874-9196@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Direclidine: Phase 3 readout est. (NCT07114874)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: NBI-1117568-SCZ3
 032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia\nEst
 imated primary completion: December 2031. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/direclidine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07114874
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
